1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 Suppl 2:ii14–ii17
2. Langley RG, Krueger GG, Griffiths CE (2005) Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64 Suppl 2:ii18–ii23 Discussion ii4–5
3. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C et al (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633–640
4. Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359:419–429
5. Gottlieb AB, Dann F (2009) Comorbidities in patients with psoriasis. Am J Med 122(1150):e1–e9